ArticleJournal of translational internal medicine2025
The roles of subcellular Argonaute 2 in cardiovascular diseases.
Article in Journal of translational internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Argonaute 2 (Ago2), the core component of the microRNA-induced silencing complex (miRNA-RISC), is a pivotal protein with a well-established and potent role in gene expression regulation. Traditionally, Ago2 functions at the post-transcriptional level by binding to non-coding RNAs in the cytoplasm, facilitating gene expression via cleavage, deadenylation, or repression of target messenger RNA (mRNA) translation. Emerging evidence indicates that Ago2 can be transported from the cytoplasm to the nucleus or mitochondria, where it performs its critical functions. We observed that nuclear and mitochondrial Ago2 have been increasingly implicated in the pathogenesis of various cardiovascular diseases, such as hypertension, diabetic cardiomyopathy, and heart failure. These findings suggest a potential novel therapeutic strategy for targeting Ago2 in cardiovascular conditions. In this review, we aim to provide a comprehensive overview of recent studies elucidating the transport mechanisms of mammalian Ago2 into various subcellular organelles and summarise the functional roles and molecular mechanisms of subcellular Ago2 in cardiovascular diseases, offering a theoretical framework for Ago2-related therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.